Addex Therapeutics
Plan-les-ouates · Founded 2002
About Addex Therapeutics
Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators for neurological disorders. Its modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecules or biological drugs. Its allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
Company Facts
- Founded: 2002
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $205.4M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2024)
- Ticker: swx:ADXN
- Website: addextherapeutics.com
- Phone: +41228841555
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/addex-therapeutics-157334 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.